Which tumor types does furmonertinib have a more effective therapeutic effect on?

Furmonertinib (Furmonertinib) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI span>), mainly used for targeted treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). EGFR mutation is one of the most common driver gene mutations in non-small cell lung cancer, especially in Asian populations. Fumetinib can selectively inhibit EGFR sensitive mutations and T790M resistant mutations, thereby effectively blocking the signaling pathways of cancer cells, inhibiting tumor proliferation and promoting apoptosis, and significantly delaying disease progression.

Clinical studies have shown that fumetinib has outstanding efficacy in patients with EGFR T790M mutation-positive advanced non-small cell lung cancer. For patients who develop resistance after first-line or second-line treatment, fumetinib can significantly prolong progression-free survival (PFS) and improve the objective response rate (ORR) of some patients. Compared with first- or second-generation EGFR-TKIs, fumetinib is more effective in drug-resistant patients and has relatively controllable side effects, making it an important treatment option for T790M-positive patients.

In addition to non-small cell lung cancer, fumetinib has also shown potential efficacy in certain solid tumors with EGFR sensitizing mutations. For example, some studies explore its application in patients with lung adenocarcinoma, lung squamous cell carcinoma and a small number of other solid tumors, especially those who are resistant to standard chemotherapy or other EGFR-TKIs. The targeting properties of fumetinib enable more precise treatment in these patients, reduce damage to non-target cells, and improve the safety and tolerability of the overall treatment.

In actual clinical application, fumetinib usually needs to be used after confirmed patients undergo EGFR gene testing to determine whether there is a sensitive mutation or T790M mutation. During use, patients need to regularly monitor blood and imaging indicators to evaluate efficacy and tolerance. The targeting mechanism and clinical efficacy of fumetinib have given it significant advantages in the treatment of EGFR mutation-related non-small cell lung cancer and some solid tumors, providing a new treatment option for patients with refractory and drug-resistant tumors.

Reference materials:https://www.drugs.com/